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Abstract
Acute promyelocytic leukemia (APL) is generally characterized by t(15;17)(q24;q21). In some cases, the classic translocation
cannot be identified by conventional methods, since the PML-RARA fusion protein results from complex, variant, or cryptic
translocation. The diagnostic algorithm of APL starts with screening methods, such as flow cytometry (FC), followed by
fluorescence in situ hybridization or polymerase chain reaction to confirm the diagnosis. Our aim was to develop a novel protocol
for analyzing APL samples based on multidimensional dot-plots that can provide comprehensive information about several
markers at the same time. The protocol included four optimized multidimensional dot-plots, which were tested by retrospective
reanalysis of FC results in APL (n = 8) and non-APL (n = 12) acute myeloid leukemia (AML) cases. After predicting the potential
position of hypergranular- and microgranular-type aberrant promyelocytes, the percentages of blast populations were examined
within the gates in all AML cases. The percentage of blasts in each predefined gate was well above the cut-off value (95%) in
APL cases in all tubes. In non-APL AML cases, the percentage of blasts in the same gates never reached the cut-off value in all
investigated tubes, and even when it did in a single tube, the pattern was markedly different from that observed in APL cases. In
conclusion, multidimensional dot-plots can be used for screening APL even in cryptic APL cases, although reproducibility across
several laboratories would require standardization of antibodies and fluorochromes. This easy-to-use and quick method can
support the diagnosis of APL and the prompt initiation of the appropriate treatment.
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Introduction
Genetic alterations determine the biological behavior of acute
myeloid leukemia (AML); therefore, these are the most effec-
tive independent prognostic factors and serve as the basis of
classifications and guidelines [1, 2]. The recommendation of
the World Health Organization (WHO) classifies AML ac-
cording to recurrent genetic abnormalities, which are associ-
ated with specific clinicopathological features. Acute
promyelocytic leukemia (APL) is mostly caused by the
PML-RARA fusion protein [3]. The promyelocytic leukemia
(PML) gene is located on chromosome 15, while retinoic acid
receptor alpha (RARA) on chromosome 17 [1]. The balanced
reciprocal classic t(15;17)(q24;q21) translocation is detected
in 90–92% of APL patients [4, 5]. In the remaining cases,
complex translocations involving chromosomes 15 and 17
or a submicroscopic insertion result in the rise of PML-
RARA transcript [1]. On the basis of the morphological ap-
pearances of aberrant promyelocytes, APL can be classified as
hypergranular or microgranular [1]. The release of
procoagulant mediators from the leukemic cells is likely the
most important mechanism, which is responsible for APL-
associated coagulopathy. Disseminated intravascular coagu-
lopathy (DIC) and systemic fibrinolysis, which usually occurs
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at the time of diagnosis, are the major causes of early death
[6–8]. The immediate administration of retinoid differentiat-
ing agents, such as all-trans retinoic acid (ATRA) and arsenic
trioxide, reduce the hemorrhagic complications of APL; more-
over, chemotherapy completed with ATRA improves overall
survival [9–13]. Therefore, rapid diagnosis and prompt treat-
ment are indispensable. The diagnostic algorithm of APL
starts with morphology and immunophenotype examinations
[2]. Classic APL is characterized by a distinct morphology;
yet, the microgranular type can mimic acute monoblastic leu-
kemia, where the clinical history also resembles APL regard-
ing coagulopathy [1, 14]. The common immunophenotypic
alterations in APL, such as CD117, CD64, cytoplasmic
MPO, CD33 bright expression, and loss or only weak inten-
sity of CD34 and HLA-DR expression, have been known for
decades; however, these are not specific for APL [1]. The
morphology and immunophenotype examination serve as
screening, and the detection of t(15;17) confirms the diagno-
sis. Fluorescence in situ hybridization (FISH) is the most com-
monly used method for the identification of t(15;17). In rare
cases of APL that do not harbor the classic cytogenetically
visible translocation but still possess the PML-RARA rear-
rangement, the polymerase chain reaction (PCR) is crucial
for detecting the fusion gene [4, 5, 15, 16].
Due to the use of multiple lasers and an increasing number
of fluorochromes, more information can be obtained from
cells by flow cytometric examinations, which lead to the in-
creasing significance of this method. Our aim was to exploit
the opportunities afforded by recent improvements in analysis
software, which can handle such large amounts of data. We
wanted to assess a new analysis protocol based on multidi-
mensional radar dot-plot that was designed to expand the ef-
fectiveness of flow cytometric examination in the screening of
APL. To test this protocol, we compared the results of an APL
AML group to those of a non-APL AML group with the help
of predefined gates around the blasts characterized by the
most common immunophenotype in APL.
Material and methods
Study design
We examined retrospectively the data of patients referred to
the Department of Laboratory Medicine (University of
Debrecen, Hungary) between May 2014 and December
2017 for detailed examination. On the basis of clinical history,
morphological, flow cytometric, cytogenetic, and molecular
examinations, two groups were formed: an APL group with
eight patients and a non-APL group with 12 patients. Six
patients with APL had classic t(15;17) translocation. One pa-
tient had complex karyotype affecting one additional chromo-
some beside chromosomes 15 and 17. Furthermore, one
patient had cryptic APL, where the fusion gene could be de-
tected only by PCR. The non-APL group was designed to
include only those AML cases, which were characterized by
myeloblasts that mimic the immunophenotype of APL. Their
myeloblasts were CD117 positive, CD33 bright, and CD34
negative—this is the immunophenotype pattern most charac-
teristic of APL. All patients in the non-APL group had normal
karyotype and mutated NPM1 because this genetic feature is
associatedwith CD34 negativemyeloblasts [17–20]. The clin-
ical and laboratory parameters of patients are summarized in
Table 1. Bone marrow aspiration samples were examined by
May-Grünwald-Giemsa staining and ×1000 magnification.
Flow cytometry
The bone marrow samples were examined routinely by eight
color-labeling procedure with a four-tube AML panel for di-
agnostic purposes. The antibodies we examined are shown in
Table 2.
CD14, CD11b, HLA-DR, CD45, CD64, CD13, CD15,
CD34, CD71, CD117, CD300e, CD4, and CD10 markers were
purchased from the Becton Dickinson Biosciences (San Jose,
CA,USA); CD33, CD16,CD2, CD117, andCD13markerswere
purchased from the Beckman Coulter (Brea, CA, USA); CD45
marker was purchased from Invitrogen (Thermo Scientific Inc.,
Waltham, MA, USA); HLA-DR marker was purchased from
Biolegend (San Diego, CA, USA), and cytoplasmic
MPO (cyMPO) was purchased from Dako (Santa Clara, CA,
USA). Generation and labeling of mouse monoclonal antibodies
against FXIII-A subunit was carried out utilizing a FITC labeling
kit (Sigma, St. Louis, MO) [21]. The labeling procedure was
Table 1 Clinical and laboratory parameters of patients
APL (n = 8) Non-APL (n = 12)
Age (year) 53 (32–74) 64 (50–80)
Gender (female/male) 4/4 9/3
WBC (×109 L) 17.01 (0.46–56.1) 88.12 (8.3–303)
Hypergranular type 9.56 (0.46–22.45)
Microgranular type 35.64 (15.2–56.1)
HB (g/L) 96 (77–115) 81 (49–138)
PLT (×109 L) 38 (8–85) 118 (28–274)
LDH (U/L) 806 (173–2266) 1345 (214–8194)
Blast% in bone marrow 63.5 (26.6–87.5) 54.8 (20.7–82.9)
DIC 8/8 0/12
FLT3 ITD (+/-/n) 3/3/2 4/8/0
FLT3 TKD (+/-/n) 0/6/2 0/12/0
NPM1 (+/-/n) 0/6/2 12/0/0
Abbreviations: WBC: white blood cell count, HB: hemoglobin, PLT:
platelet count, FLT3 ITD: FLT3 internal tandem duplication, FLT3
TKD: FLT3 tyrosine kinase domain, NMP1: nucleophosmin, n: not done
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performed as previously described [22]. One hundred thousand
events were acquired with the help of FACS Canto II flow
cytometer (Becton Dickinson Biosciences, San Jose, CA,
USA). To make the results comparable, the flow cytometer was
calibrated daily, using cytometer setup and tracking fluorescent
microbeads (Cat No. 641319, Becton Dickinson Biosciences,
San Jose, CA, USA) and Autocomp software as recommended
by the manufacturer. Data was analyzed by Kaluza Software
version 1.2 (Beckman Coulter, Brea, CA, USA).
Bivariate dot-plots were used to analyze the detailed
immunophenotype of leukemic cells. The threshold of posi-
tivity was set to > 10% positive leukemic cells for MPO and to
> 20% for all other antigens, in accordance with the threshold
conventions apparent in the literature [1, 23].
To create an analysis protocol for APL, one multidimen-
sional radar dot-plot was optimized for each of the four tubes.
The software allows selecting the number and the position of
parameters in the radar dot-plot, which influence the appear-
ance of blast population in the dot-plot. The optimization pro-
cedure was the following: First, the files of three AML pa-
tients characterized by different morphology (M2, M4, APL)
were merged, and then the three blast populations were gated
by CD45/SSC bivariate dot-plot. Subsequently the three dif-
ferent blast populations were presented in one radar dot-plot,
and those parameters and locations were selected whereby the
three populations differed from each other the most (for tube
1, these were SSC, CD4, CD64, CD11b, CD13, HLA-DR,
CD14, CD300e, CD45; for tube 2, CD15, CD123, SSC,
CD34, CD13, HLA-DR, CD45, for tube 3, CD34, CD117,
CD56, CD45, CD33, SSC, and for tube 4, these were
cyFXIII-A, cyMPO, HLA-DR, SSC, CD117, CD45).
Finally, we merged all hypergranular APL cases to designate
gates for the expected positions of 95% (cut-off value) of
hypergranular APL blast populations. Because the location
of microgranular-type APL differed from hypergranular cases,
a microgranular gate could be defined on the basis of the two
microgranular cases.
Chromosome analysis, FISH, and molecular analysis
G-banding was performed according to standard procedures
on all samples of APL and non-APL patients. Karyotypes
were described according to the International System of
Human Cytogenetic Nomenclature. Fluorescence in situ hy-
bridization was carried out on cell suspension samples used
for chromosome analysis according to the manufacturer’s in-
structions, using PML/RARA DC, DF translocation probes
(Metasystems, Altlussheim, Germany).
Statistical analysis
Considering the low number of samples median, 25th and
75th percentile values were used. Statistical analysis and the
creation of figures were carried out using GraphPad Prism 6.0
(GraphPad Software, San Diego, CA, USA) statistical
program.
Results
Morphological characterization of patients with APL
and non-APL AML
In the APL group, two patients displayed microgranular- and
six patients with hypergranular-type APL. The myeloblasts of
three patients in the non-APL group were characterized by
agranular cytoplasm, showing distinct blebs, or pseudopod
formation. Two patients had Bcup-like^ blasts. According to
the French-American-British (FAB) classification, five of the
remaining cases exhibited M4 morphology, one M0/M1, and
one M2. The representative morphologic appearance of blasts
in the APL is shown on Online Resource 1, respectively.
Immunophenotypic characterization of patients
with APL and non-APL AML
In accordance with the findings of the morphological exami-
nation, the aberrant promyelocytes had high side scatter (SSC)
in six cases (hypergranular type) and medium intensity SSC in
two cases (microgranular type). The immunophenotypes of
promyelocytes are summarized in Table 3. Aberrant
promyelocytes were characterized by a frequently detected
pattern in APL: in hypergranular cases, promyelocytes
expressed only CD117 of blast markers, while they expressed
all myeloid markers (CD33, CD13, cyMPO) with high inten-
sity. Blasts were CD15 negative in all cases. Regarding
leukemia-associated immunophenotype (LAIP) and prognos-
tic markers, CD56 and CD2 were positive in one case, while
cytoplasmic FXIII-Awas positive in all cases.
In the non-APL group, myeloblasts (MB) were character-
ized by monocytic immunophenotype in five cases, in accor-
dance with the morphological findings. CD123 and cyFXIII-
Awere positive in 75% of the cases (Table 3).
Multidimensional map of APL
Regardless of the mechanism that lead to the formation of the
PML-RARA fusion protein, more than 95% of blasts detected
in the hypergranular gate were observed in all hypergranular-
type APL cases (Fig. 1a). As for the microgranular-type APL
cases, the position of the blast population differed fromwhat we
found in the hypergranular-type APL cases; therefore, dedicated
gates were set up to predict the position of microgranular blasts
(Fig. 2). The microgranular blasts were located within their
respective gate (the median percentages of blasts within the
microgranular gate were 96.1% for tube 1, 96.5% for tube 2,
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98% for tube 3, and 97% for tube 4). The percentage of blasts
was well above not only the cut-off value (95%) in both hyper-
and microgranular-type APL AML cases in all the four tubes
(Fig. 1) but also the patterns of blasts within the gates corre-
sponding to their types that were similar in all the cases.
In most cases of the non-APL AML patient group, blasts
within the gate typically did not reach the cut-off value. It was
only in tube 3—which contained the criteria markers (CD117,
CD34) used for creating the non-APL AML group—that the
percentage of blasts in the hypergranular gate surpassed the
cut-off value (Fig. 1); but even here, the pattern of the blasts
within the gate differed from what we detected in the APL
AML group: the blasts were not dispersed evenly throughout
the gate but concentrated in its upper segment (Fig. 2, tube 3).
Similarly to the hypergranular APL gates, there were only one
non-APL AML case which reached the cut-off value in the
pre-defined microgranular gate in tube 1, and in some cases,
the percentage of MB in the microgranular-type gate
approached the cut-off value. The pattern of MB in the
microgranular gate, however, differed from the position of
microgranular APL cells. The representative multidimension-
al dot-plots in the APL and non-APL AML groups are shown
in Figs. 2 and 3.
Discussion
The major finding of our study was that with the help of
predefined gates in a multidimensional radar dot-plot, an ef-
fective, reproducible, and quick protocol can be created for the
screening of APL. Recently, routinely used flow cytometric
analyzing software (e.g., Kaluza and Infinicyt) allows inte-
grated data visualization, which improves the interpretation
of a large amount of data generated by an increasing number
of fluorochromes. The comprehensive dot-plots were used
first in the identification of normal cell populations during
maturation [24, 25]. When the position of normal cell types
was mapped, on the one hand, the detection of alterations from
the normal pattern permit the identification of characteristic
dysplastic signs referred to as myeloproliferative disorders
[24]. On the other hand, several studies have demonstrated
that the appearance of aberrant cells on integrated dot-plots
was associated with a distinct malignancy, which can be uti-
lized in the detection of minimal residual disease [26–28].
To the best of our knowledge, we were the first to examine
APL with multidimensional dot-plots based on a wide range
of markers. We used not only the markers the expression of
which was frequently altered in APL (CD34, CD117, HLA-
DR, CD15, cyMPO, CD13, CD33, CD64) but also the prog-
nostic markers, such as CD56, CD7, CD2, and cyFXIII-A [22,
29–32]. The expression of CD56 or CD7 marker is associated
with poor prognosis [29], while the presence of cyFXIII-A or
CD2 with good prognosis [22, 31].
We found that the aberrant promyelocytes can be character-
ized by unique patterns and positions on radar dot-plots regard-
less of the mechanism leading to the formation of PML-RARA
fusion protein. Therefore, the results of these dot-plots can
Table 3 Antigen expression by leukemic cells
APL Non-APL AML
hypergranular
type (n = 6)
microgranular
type (n = 2)
n = 12
CD117 100% 100% 100%
CD34 0% 100% 0%
HLA-DR 0% 0% 58%
CD33 100% 100% 100%
CD13 100% 100% 100%
cyMPO 100% 100% 83%
CD14 0% 0% 42%
CD11b 0% 0% 42%
CD64 50% 50% 42%
CD4 0% 0% 42%
CD15 0% 0% 42%
CD123 0% 100% 75%
CD56 17% 0% 25%
CD38 100% 100% 100%
CD7 0% 50% 25%
CD2 17% 100% 0%
cyFXIII-A 100% 100% 75%
Table 2 Antibody combinations
used in flow cytometric
examination for the diagnosis of
AML
FITC PE PerCP-Cy5.5/PC5.5 PC7 APC APC-AF750 PB PO
1. CD14 CD11b HLA-DR CD13 CD300e CD64 CD4 CD45
2. CD15 CD123 CD34 CD13 CD10 CD16 HLA-DR CD45
3. CD71 CD117 CD33 CD56 CD34 CD38 CD7 CD45
4. cyFXIII-A cyMPO CD33 CD2 CD34 CD117 HLA-DR CD45
Abbreviations: cyFXIII-A: cytoplasmic A subunit of blood coagulation factor XIII; cyMPO: cytoplasmic
myeloperoxidase, FITC: fluorescein isothiocyanate, PE: phycoerythrin, PerCP-Cy5.5: peridinin chlorophyll pro-
tein 5.5, PC5.5: phycoerythrin cyanin 5.5, PC7: phycoerythrin cyanin 7, APC: allophycocyanin, APC-AF750:
conjugation allophycocyanin-alexa fluor 750, PB: pacific blue, PO: pacific orange
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support the diagnosis of APL even in FISH-negative—cryp-
tic—cases and indicate the performance of PCR examination
as early as possible to confirm the diagnosis.
In addition, with the help of multidimensional dot-plots,
more information can be obtained from blast cells with a single
examination; therefore, APL cases can be differentiated from all
types of AML, including CD34-negative cases. Earlier several
studies confirmed the usefulness of bivariate dot-plots in the
screening of APL cases within AML. These were based only
on three or four markers, usually CD34, HLA-DR, and a
marker indicative of maturation, such as CD15 or CD11b [30,
33, 34]. These bivariate dot-plots, however, were characterized
by high specificity and sensitivity (> 90%) only with respect to
all types of AML, most of which are CD34-positive cases. Our
novel protocol based on multivariate dot-plots, in turn, brings
the most value where the applicability of bivariate dot-plots is
limited: differentiating between APL and AML with CD34-
and/or HLA-DR-negative immunophenotype. More and more
information has been accumulated over the past decade about
this less common type of AML. It is characterized by normal
Fig. 2 Representative dot-plots for various APL cases. Representative
dot-plots of a hypergranular type APL with classic translocation are in
the first line, dot-plots of hypergranular type APL with cryptic transloca-
tion are in the second, and microgranular type APL are in the third line.
The bold frame indicates the hypergranular-gate, and gray one indicates
the microgranular-gate. Red indicates blasts. The bold numbers indicate
the percentage of blasts in gates predicted for one of the pre-defined type
of APL-gate
Fig. 1 The percentage of blasts in hypergranular- (a) and microgranular-
type gates (b). The black triangles indicate hypergranular APL cases, the
white ones the microgranular-type APL cases, while the gray circles
indicate non-APL AML cases. The horizontal line represents the cut-off
value (95%)
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karyotype, NPM1 mutation, and morphologically by Bcup-
like^ blasts and M2 or M4 morphology as defined by FAB
[17–20, 35, 36]. Despite these common denominators, mor-
phology suggests that this is not a homogeneous subtype of
AML, and yet, another advantage of our protocol is that it can
detect various patterns among CD34-negative non-APL cases.
Thus radar dot-plots enable the more precise identification of
similarly behaving AML cases.
It must be acknowledged that there are some limitations to this
study. For three reasons, we were able to examine only a rela-
tively small number of APL cases. First, APL is relatively un-
common in Hungary; secondly, radar dot-plots can be used to
compare cases where the same antibodies and fluorochromes
have been used; and thirdly, the eight-color staining method
has been used in Hungary only since 2014. Therefore, a control
study on a larger population would be necessary in order to
validate our results. In addition, we examined only APL cases
with PML-RARA fusion, but RARA may have other fusion part-
ners, such as ZBTB16, NUMA1, STAT5B, or NPM1. The variant
fusion partner is important because it can influence the prognosis
through the response to ATRA. Sainty et al., who examined a
large number of cases with APL lacking t(15;17), found that
ZBTB16-RARA cases were associated with CD56 expression,
and there were no other immunophenotypic differences from
t(15;17) APL [37], which suggests that our multidimensional
screening protocol could be used in those cases as well.
In conclusion, multidimensional (radar) dot-plots can be
used for screening APL even in cryptic APL cases. Based
on only four multidimensional dot-plots, our protocol exam-
ined 6–9markers per tube at the same time, thus increasing the
efficiency and effectiveness of the FC examination. This
method is reproducible (within the same laboratory), easy-
to-use, and quick regardless of the percentage of blasts size
and can differentiate squarely between APL and non-APL
AML cases even when the FC results based on bivariate dot-
plots would be uncertain and suggest APL falsely. This differ-
entiation is crucial, because APL requires the prompt admin-
istration of special treatment to achieve a favorable prognosis.
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Fig. 3 Representative dot-plots for various non-APL AML cases. Dot-
plots of a non-APL AML with cup-like blasts are in first line, dot-plots of
non-APL AML with blasts characterized by agranular cytoplasm, show-
ing distinct blebs, or pseudopod formation are in the second and dot-plots
of a non-APL with M4 morphology are in third line. The bold frame
indicates the hypergranular-gate, and gray frame predicted
microgranular-APL. Red indicates blasts; pink represents monocytes.
The bold numbers indicate the percentage of blasts in gates predicted
for hypergranular-type APL and represent the percentage of blasts in
gates predicted for microgranular-type APL
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